STRIDES PHARMA SCI LTD Fair Value
STAR · Healthcare · Current price ₹1,021
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹373 | 20% ROE fading to 13% over ~3 yrs, on ₹337 book |
| Relative P/E | ₹1,830 | EPS × 30.3 peer-median P/E |
| Graham floor | ₹676 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | ₹1,410 | Street consensus 12-month target price |
Is STRIDES PHARMA SCI LTD undervalued?
DocStoX estimates the fair value of STRIDES PHARMA SCI LTD at ₹934 per share, versus the current market price of ₹1,021. That puts the stock about -8.5% above our fair-value estimate, which we read as "Fairly Valued". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹373), Relative P/E (₹1,830), Graham floor (₹676), Analyst target (₹1,410). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹373 (bear) to ₹934 (base) to ₹1,830 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on STRIDES PHARMA SCI LTD
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.